Topics:
Gastrointestinal Cancers • Medical Oncology • Liver and Pancreas Tumors • NCI-CCC Tumor Board Question • Rutgers • NCI-CCC GI Tumor Board Question • Hepatocellular Carcinoma
What is your platelet cutoff for atezolizumab + bevacizumab in HCC in the absence of bleeding (variceal or otherwise)?
Answer from: Medical Oncologist at Academic Institution
The platelet eligibility for IMBrave150 was 75K, I believe. Eligibility in the original SHARP trial was 60K, so I often consider somewhere around 60K. Although if truly no varices on EGD and no history of bleeding, I might consider down to 50K. Lower than that, I would probably think single agent ch...
Sign in or Register to read more